Scholar Rock jumps 12% after FDA approves isembyld for spinal muscular atrophy (SRRK:NASDAQ)
Scholar Rock jumps 12% after FDA approves isembyld for spinal muscular atrophy (SRRK:NASDAQ) Seeking Alpha
Finance, IT & News
Scholar Rock jumps 12% after FDA approves isembyld for spinal muscular atrophy (SRRK:NASDAQ) Seeking Alpha
FDA Approves Isembyld, First SMA Treatment To Target Muscle Loss Dallas Express
Fitch Ratings: 1/1 renewals will have T&Cs focus and be ‘less price led’ Insurance Times
S&P Affirms Saudi Arabia’s A+ Rating With Stable Outlook CairoScene
Moody’s downgrades Flowers Foods rating on slow deleveraging Investing.com